#monoclonal antibody
Text
Monoclonal Antibodies
So I listened to a talk from a drug rep the other day who came into the clinic to promote Cytopoint, the anti-allergy injection for dogs.
It’s a great drug, overall. Super useful for many, literally life changing for a few, and now a mainstay of the allergy treatments we offer. But I had to laugh at something the rep said:
“It’s not really a drug. It’s a bio-mimicry molecule! It’s replicating normal molecules that would be found in the body and just providing more of them!”
And I’m sitting here thinking: that is still totally a drug. A drug is any substance which when given to a living organism produces a physiological effect. 10mg of lokivetmab is most definitely a drug.
But if you are going to argue that Cytopoint is not a drug because it mimics a natural molecule found in the body, then by that logic neither are insulin, thyroxine, cortisone or just about every single hormone.
For goodness sake. I have to wonder what planet marketers live on some days.
We also had a bit of a debate because we’re widely told that Cytopoint shouldn’t have any side effects. Partly this is because monoclonal antibodies aren’t well known in veterinary medicine and they haven’t been around that long.
They’re certainly much safer than the equivalent drugs in other classes, but they’re not ‘side effect free’. They’re a protein, so it’s theoretically possible to be allergic to it. Like the Kesimpta I take it seems likely that some dogs will be ‘off colour’ for a day or so. The most common side effect is being quiet the next say, so it is pretty mild for a typical dog and still worth it. But it’s not zero.
Having a headache for a day is much milder than having acute kidney failure, but I wonder if we’ll get more reports in the future of extremely sporadic weird side effects as we gain more experience with this class of medication.
Medical advancements are wonderful and exciting. But don’t let marketers do all the talking!
And remember to report side effects to the manufacturer.
271 notes
·
View notes
Text
#eosinophilic gastritis#chronic illness#eosinophilic disorders#chronic illness meme#rare disease#EoG#eosinophilic disease#eosinophilic gastrointestinal disorders#eosinophilic gastrointestinal disease#monoclonal antibody#immune system disorder#immune system#pharmacology#biotech#biotechindustry#medication#medicine#rare disorders#il-5#fasenra#interleukin-5#benralizumab
3 notes
·
View notes
Text
0 notes
Text
Explore the process of monoclonal antibody production and how it enhances the immune response. Learn how Changyubio is at the forefront of this field.
https://www.changyubio.com/monoclonal-antibody-production/
#monoclonal antibody#antibody production#Freund's Adjuvant#quick immune adjuvant#aqueous adjuvant#polyclonal antibody production
0 notes
Link
0 notes
Text
Nirsevimab
(Heavy chain)QVQLVQSGAE VKKPGSSVMV SCQASGGLLE DYIINWVRQA PGQGPEWMGG IIPVLGTVHYGPKFQGRVTI TADESTDTAY MELSSLRSED TAMYYCATET ALVVSETYLP HYFDNWGQGTLVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFPAVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPAPELLGGPSVF LFPPKPKDTL YITREPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKPREEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG…
View On WordPress
#1989556-22-0#antiviral#APPROVALS 2022#AstraZeneca AB#EU 2022#MED-18897#MEDI8897#Monoclonal antibody#Nirsevimab#peptide#respiratory syncytial virus infection
1 note
·
View note
Text
Chimering interferon on a myeloma receptor: meet modakafusp and its "single-agent" abilities
Chimering interferon on a myeloma receptor: meet modakafusp and its “single-agent” abilities
According to the American Cancer Society, about 12,640 deaths from multiple myeloma are expected to occur in the U.S. in 2022. The cancer is uncommon, affecting less than 1% of the population, especially elder people over the 75 of age. Myeloma is currently not curable, and despite advances in treatment, all patients see their cancers relapse after initial treatment and other early lines of…
View On WordPress
#anticancer drug#clinical trial#daratumumab#immune receptor#immune system#isatuximab#modakafusp#monoclonal antibody#multiple myeloma
0 notes
Text
0 notes
Text
New Drugs Target Cancer Cells
New Drugs Target Cancer Cells
Treatments for multiple myeloma have grown a great deal in the past few years. Newer drugs help people with this blood cancer live longer and enjoy a better quality of life.
Several drugs have been approved to treat multiple myeloma since 2015. Some can help when the disease comes back after treatment (called a relapse) or when the cancer doesn’t respond to the first line of treatment (called…
View On WordPress
0 notes
Text
The ✨Joys✨ of Kesimpta
(With a medium amount of sarcasm).
Kesimpta is a monoclonal antibody named Ofatumumab which targets the B cells of my immune system to discourage them from demyelinating my spine and brain. It’s a very targeted therapy, these artificial antibodies only target one protein, and yet the side effect profile continues to be an interesting and unpredictable experience.
But firstly: does it work? Yeah, pretty well so far. Minimal progression, actually some improvement across most symptoms, and I will willingly trade the one day a month or so of side effects I have to endure for the medication that will hopefully keep me functional as long as possible. I will probably never go back to performing surgery, and there are bad days here and there, but the burning arm pain doesn’t happen anymore and the numbness is generally restricted to just hands, not the whole limb.
The side effects though, they have been… interesting. They’ve certainly lessened over time as I adjust to the medication, but it’s such a random grab bag of effects.
You get warned when you start this medication that it will cause a bit of a headache, so to take some Panadol. But what happened for me:
First two hours after the injection - nothing happened at all
Then the migraine came, plus heavy fatigue.
Then the shivering started, I had chills so bad that I was filling hot water bottles with boiling water to hug in my bed, because it was the only way I wouldn’t tremble constantly.
Then came the gastro signs, while I still had the chills.
Unrelenting insomnia approximately 12 hours after the dose.
The chills dissipated overnight but the nausea continued the next day, plus dizziness and exhaustion.
And I got to do that once a week for the first few doses, so I was pretty much non functional other than keeping myself alive at that point.
Over time, the side effects have been steadily less and less though. If I’m a little bit unwell in some way before a dose, the Kesimpta will exaggerate the symptoms, and I try and time the dose so I can sleep through most of the nausea and headache. I’m usually a bit off balance for most of the day, not enough to be a fall risk but aware enough that I am not right enough to drive and definitely shouldn’t climb a ladder.
But I still get these completely bizarre mood swings. I can go from being okay to crying over a sad thought in about 20 minutes, over no meaningful stimulus. I’m watching myself react this way and just have to ride it out, but there’s no way I could go to work on a medication day. People will think I’m insane or on a recreational drug.
So I have to take the day as a scheduled maintenance day.
Being on this medication has made me very glad for the Medicare system we have in Australia, and the pharmaceutical benefits scheme which subsidises the cost of a lot of medications through the government.
Without these systems, Kesimpta would be costing me about $2.5k per month. As it is now, it costs me about $60 a month, delivered, and I get a handy little ap that reminds me when my dose is due, and will send me an email or text message if it thinks I’ve missed a dose, steadily getting more frequent so that I will get a text message every hour as a reminder if it thinks I’ve forgotten.
247 notes
·
View notes
Text
New drugs target cancer cells
New drugs target cancer cells
Treatments for multiple myeloma have grown tremendously in recent years. Newer drugs help people with this blood cancer live longer and enjoy a better quality of life.
Since 2015, several drugs have been approved for the treatment of multiple myeloma. Some may help when the disease comes back after treatment (called a relapse) or when the cancer doesn’t respond to the first line of treatment…
View On WordPress
0 notes
Text
the way every st actor hates the straight ships is so funny
like every time the methane vermins are brought up finn looks like he wants to jump off a cliff
noah is so YAY BYLER GO BYLER WOOOO like our very own fucking cheerleader so obvi hes not big on the mcchicken train either
every time anyone asks natalia abt steve or jon shes like UM SORRY DIDNT HEAR ANYWAY WHAT DO U GUYS THINK OF ROBIN??? ITS NICE FOR NANCY TO HAVE A GF ISNT IT?????
caleb adores lumax but also thinks mycelium virus isnt real love 💀
sadies an elmax stan
gaten ships steddie
like all of them are rooting for the little gay people and thats something that can be so special🥰
#every time anything to do with monoclonal antibodies gets brought up finn literally looks like someone just spat on his shoes#its so fucking funny#'oh yeah. the ship name.😒' GIRLQUEEN????#also natalias mission to never discuss the jon steve nance triangle ever again is so funny 💀💀#shes just like hey guys arent woman great yeah nancy loves women she and robin should run away into the sunset tgthr#its just so slay they literally all slander the het ships in favour of the gay ones all the time#well. most of them#anyway#byler
190 notes
·
View notes
Text
Nearly 5 weeks until my first written GCSE. Where did this year go. Seriously. I want it back
#i swear to god#i literally just started year 11#you're telling me biology paper 1 is on April 17th??#you're telling me i have to understand monoclonal antibodies by then???
5 notes
·
View notes
Text
Ozoralizumab
Ozoralizumab
FormulaC1682H2608N472O538S12CAS 1167985-17-2Mol weight38434.3245
PMDA JAPAN APPROVED 2022 2022/9/26 Nanozora
anti-TNFα Nanobody®; ATN-103; Nanozora; PF-5230896; TS-152
Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[1]
Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to…
View On WordPress
#APPROVALS 2022#ATN 103#JAPAN 2022#Monoclonal antibody#nanobody#Nanozora#Ozoralizumab#Treatment inflammation
1 note
·
View note
Text
Sulfatase-2: the TNF-alpha's goonie paving the ground to antigen presentation and cytokine actions
Sulfatase-2: the TNF-alpha’s goonie paving the ground to antigen presentation and cytokine actions
Extracellular sulfatase-2 (Sulf-2) is an enzyme that influences receptor-ligand binding and subsequent signaling by chemokines and growth factors. The role of Sulf-2 remains unexplored in inflammatory cytokine signaling in the context of rheumatoid arthritis (RA). Scientists have now doscovered that sulfatase-2 that plays a critical role in the damage caused by rheumatoid arthritis.…
View On WordPress
#autoimmune disease#chronic pain#cytokines#heparan-sulphate#joint damage#macrophages#monoclonal antibody#phagocytosis#proteoglycans#rheumatoid arthritis#sinovial cells#sulfatase
0 notes
Last Seen Blogs
